Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

Fig. 4

Plot boxes of serum inflammatory molecules and cells in the study cohorts. Serum levels of NLRP3 inflammasome (pg/mL), Caspase-1 (ng/mL) and Interleukin-1β (pg/mL) in diabetic SGLT2-I users (N = 111) and diabetic Non-SGLT2-I users (N = 258) at baseline (T0), after 24 h (T1), 6 months (T2) and 12 months (T3) of follow-up (A–C). Serum levels of CD86 as a marker of M1 macrophages (U/mL) and CD206 (ng/mL) in diabetic SGLT2-I users (N = 111) and diabetic Non-SGLT2-I users (N = 258) patients at baseline (T0), after 24 h (T1), 6 months (T2) and 12 months (T3) of follow-up (D, E). Values are reported as mean ± SD. NLPR3 NLR family pyrin domain containing 3 (NLRP3) inflammasome, SGLT2-I sodium glucose transporter 2 inhibitors. **P < 0.01 vs SGLT2 users at same T; ^^P < 0.01 vs SGLt2 non-users at baseline

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840